Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Tamm-Horsfall protein augments neutrophil NETosis

ABSTRACT: Proteome profiles of isolated peripheral human neutrophils pretreated with purified Tamm-Horsfall protein and stimulated to undergo NETosis with PMA.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Antrix Jain

LAB HEAD: Kathryn Patras

PROVIDER: PXD045468 | Pride | 2024-09-23

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	51066_1_EXP_914_hs_TMT16_prof_250ng_F01.mokapot.psms.txt	Txt
	51066_1_EXP_914_hs_TMT16_prof_250ng_F01.pepXML	Pepxml
	51066_1_EXP_914_hs_TMT16_prof_250ng_F01.raw	Raw
	51066_1_EXP_914_hs_TMT16_prof_250ng_F02.mokapot.psms.txt	Txt
	51066_1_EXP_914_hs_TMT16_prof_250ng_F02.pepXML	Pepxml

Items per page:

1 - 5 of 75

Similar Datasets

Single cell RNASeq of murine bone marrow derived macrophages (BMDM) treated with non-polymerizing Tamm-Horsfall Protein

Project description:To elucidate changes in macrophage subpopulations in the presence of non-polymerizing Tamm-Horsfall Protein, we performed single cell RNAseq on mouse bone marrow derived macrophages following 18 hour treatment with either a non-polymerizing form of Tamm-Horsfall Protein or vehicle. After treatment, cells were harvested and dead cells removed prior to sorting on a 10X Chromium platform version 3 and generation of libraries. Sequencing was perfomred on an Illlumina NovaSeq 6000.

2022-06-23 | GSE189433 | GEO

Comparison of protein expression alterations in Menin inhibitor-sensitive and tolerant/resistant AML cells with or without Menin inhibitor treatment

Project description:AML MV4-11, OCI-AML3 and Menin inhibitor tolerant resistant MV4-11-MITR, and OCI-AML3-MITR cells were treated with 500 nM of SNDX-50469 for 48 hours to determine the global protein expression alterations that correlate with the tolerant/resistant phenotype compared to parental controls as well as the response of each cell type (sensitive or tolerant/resistant) to treatment with Menin inhibitor.

2026-09-03 | PXD053575 | Pride

Effect of CDK7 inhibitor, FHD-286, SNDX-50469, or Tasquinimod on protein expression alterations in patient-derived secondary AML or de novo MLL1-rearranged AML cells

Project description:Patient-derived secondary AML cells were treated with 100 nM of SY-5609 for 24 hours, 100 nM of FHD-286 for 48 hours, or 20 µM of Tasquinimod for 48 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment with a CDK7 inhibitor, chromatin remodeling inhibitor, or S100A8/S100A9 inhibitor or in secondary AML cells. Patient-derived de novo AML cells with MLL1 rearrangement and Menin T349M mutation were treated with 100 nM of FHD-286 or 500 nM SNDX-50469 for 48 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and/or lethal effects of treatment with a chromatin remodeling inhibitor, FHD-286, or a Menin inhibitor SNDX-50469 in MLL1 rearranged AML cells

2025-04-28 | PXD053548 | Pride

Effect of CDK7 inhibitor on protein expression alterations in cultured secondary AML HEL92.1.7 cells

Project description:HEL92.1.7 cells in exponential growth phase were treated with 100 nM of SY-5609 for 24 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment with a CDK7 inhibitor in secondary AML cells.

2025-04-28 | PXD053572 | Pride

Effect of SMARCA2/SMARCA4 inhibitor, FHD-286, on protein expression alterations in cultured cell line or patient-derived AML cells with MECOM rearrangement and expression of EVI1

Project description:Cultured cell line UCSD-AML1 (45,XX,-7,t(3;3)(q21;q26)) and patient-derived AML194 (acute myeloid leukemia with inv3(q21;q26.2)) cells were treated in duplicate with 0 nM or 100 nM of FHD-286 for 48 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment with a small molecule, chromatin remodeling complex protein, dual SMARCA2/SMARCA4 enzymatic activity inhibitor in MECOM rearranged AML cells with EVI1 overexpression. We also compared the global expression changes that were common between the two FHD-286-treated AML subtypes.

2026-01-23 | PXD059060 | Pride

Project title: Effect of FHD-286 or BRG1/BRM degrader AU15330 on protein expressions in MLL1-rearranged AML cells

Project description:MOLM13 cells and patient-derived de novo AML cells with MLL1 rearrangement were treated with 100 nM of FHD-286 or 100 nM of AU15330, a dual BRG1/BRM protein degrader for 48 hours. The goal was to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and/or lethal effects of treatment with a chromatin remodeling inhibitor, FHD-286, or a BRG1/BRM protein degrader in MLL1-rearranged AML cells.

2025-04-28 | PXD055994 | Pride

Effect of BET inhibitor, mivebresib, dactolisib or LCL-161 on protein expressions in AML cells with MECOM rearrangement and high expression of EVI1

Project description:Patient-derived AML194 (acute myeloid leukemia with inv3(q21;q26.2)) cells were treated in duplicate with 0 nM or 500 nM of mivebresib, 500 nM of dual PI3K/mTOR inhibitor dactolisib or 1000 nM of IAP antagonist LCL-161 for 24 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment with these small molecules in MECOM-rearranged AML cells with EVI1 overexpression.

2026-02-16 | PXD063413 | Pride

Effect of SMARCA2/SMARCA4 inhibitor, FHD-286, on protein expression alterations in cultured cell line or patient-derived AML cells with MECOM rearrangement and expression of EVI1

Project description:Patient-derived AML191 (acute myeloid leukemia with inv3(q21;q26.2)), -7) cells were treated in duplicate with 100 nM of FHD-286 for 0, 8, 16, 24 and 48 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment with a small molecule, chromatin remodeling complex protein, dual SMARCA2/SMARCA4 enzymatic activity inhibitor in MECOM-rearranged AML cells with EVI1 overexpression.

2026-01-23 | PXD059059 | Pride

Determination of protein expression changes due to treatment with chromatin remodeling inhibitor FHD-286 in patient-derived mutant NPM1 and FLT-ITD-expressing AML cells

Project description:We treated patient-derived mutant NPM1-and FLT3-ITD expressing AML cells with a chromatin remodeling inhibitor, FHD-286, at a dose of 100 nM, for 48 hours to determine FHD-286-mediated changes to the AML proteome.

2025-05-06 | PXD047967 | Pride

Determination of protein expression changes due to treatment with chromatin remodeling inhibitor FHD-286 in MLL1-rearranged AML cells

Project description:We treated MLL1-rearranged AML MOLM13 cells with a chromatin remodeling inhibitor, FHD-286, at a dose of 100 nM, for different time intervals (up to 48 hours) to measure the time-dependent changes to the AML proteome

2025-05-26 | PXD047965 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data